Virion Therapeutics, LLC, a clinical-stage biotechnology company developing novel T cell-based immunotherapies that utilize checkpoint modifiers, today announced at the 33rd Conference on Retroviruses ...
To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min Virion was recently awarded a ...
The Indian vaccine BBV152 is a whole-virion inactivated severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine based on Asp614Gly variant and has been formulated with the toll-like ...
PHILADELPHIA, Oct. 12, 2023 /PRNewswire/ -- Virion Therapeutics, LLC, a clinical-stage biotechnology company developing novel T cell-based immunotherapies, and Ocean Biomedical, Inc. (NASDAQ: OCEA), a ...
To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min Both Virion Therapeutics and ...
PHILADELPHIA, Oct. 26, 2023 /PRNewswire/ -- Virion Therapeutics, LLC, a clinical-stage biotechnology company developing novel T cell-based immunotherapies, and its Joint Venture partner, Ocean ...
Membrane proteins are key targets for therapeutic intervention using antibody biologics. Over 60% of FDA-approved drugs act on these proteins. Studying them is challenging because the proteins must be ...
A virion is “the complete, infective form of a virus outside a host cell, with a core of RNA or DNA and a capsid.” It is the infectious form of the virus as it moves between cells and hosts. A year ...
Ongoing safety (N=25) and immunogenicity (n=22), and first report of anti-HBV activity, presented in chronically HBV-infected patients following a single, prime-only intramuscular injection of ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results